Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986956 | 0.90 | GLS (1.00) | GLS | |
| SCHEMBL28803841 | 0.85 | GLS (0.61) | GLS | |
| SCHEMBL17396921 | 0.85 | GLS (0.90) | GLS | |
| SCHEMBL19558976 | 0.84 | GLS (0.87) | GLS | |
| SCHEMBL29678831 | 0.82 | GLS (0.71) | GLS | |
| SCHEMBL14976200 | 0.82 | GLS (0.71) | GLS | |
| SCHEMBL15864067 | 0.79 | GLS (0.65) | GLS | |
| SCHEMBL17396667 | 0.79 | GLS (0.77) | GLS | |
| SCHEMBL14986966 | 0.78 | GLS (1.00) | GLS | |
| SCHEMBL14977454 | 0.77 | GLS (1.00) | GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954686-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | Calithera Biosciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954686-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | Calithera Biosciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. | 2021-09-23 | — | — | US | disclosed |
| EP-2920168-B1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-2920168-B1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | CALITHERA BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| WO-2014089048-A1 | TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014078645-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| WO-2014078645-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | CALITHERA BIOSCIENCES, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8604016-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793535-B2 | Heterocyclic glutaminase inhibitors | GLS, GLS2, GLUL | GLS 1/4885 |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | GLS 1/4885 |
| US-20210292289-A1 | HETEROCYCLIC GLUTAMINASE INHIBITORS | GLS, GLS2, GLUL | GLS 1/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.